共 146 条
[1]
Hylek EM(1994)Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 897-902
[2]
Singer DE(2005)The pharmacogenetics of coumarin therapy Pharmacogenomics 6 503-513
[3]
Voora D(1989)Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 144-152
[4]
McLeod HL(2016)Natural history of bleeding and characteristics of early bleeders among warfarin initiators—a cohort study in Finland Clin Epidemiol. 8 23-35
[5]
Eby C(2000)Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160 41-46
[6]
Gage BF(2015)Warfarin pharmacogenetics Trends Cardiovasc Med 25 33-41
[7]
Landefeld CS(2016)Pharmacogenetics and oral antithrombotic drugs Curr Opin Pharmacol. 27 38-42
[8]
Goldman L(2008)CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study Clin Pharmacol Ther 83 460-470
[9]
Rikala M(2002)Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance Clin Pharmacol Ther 72 702-710
[10]
Kastarinen H(2004)Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin Clin Pharmacol Ther 75 204-212